Skip to content
Head to head

Sellas Life Sciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: SLS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

SLS +868.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
SLSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price13.66515.02
Change today-8.08%-1.08%
1-year return+835.6%+22.0%
Market cap$2.78B$130.58B
52-week range1.39 – 24.89412.27 – 568.67
Valuation
P/E (TTM)-68.3033.14
P/E percentile, own 5-yr range8th99th
P/B21.116.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.2515.32
Net profit (TTM)$-50.96M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin90.0%85.5%
Operating margin-4195.0%33.1%
Net margin-4130.1%30.7%
Free cash flow (TTM)$-27.30M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership37.6%96.8%
Insider activity (12mo)41 buy / 6 sell28 buy / 22 sell
Short interest (% of float)28.3%1.9%
Analyst consensus100% buy (1)95% buy / 5% hold (21)
Analyst price target$30 (+120%)$624 (+21%)
StockVane view
StockVane Quant RatingC (100)C (68)
Company
Employees136,400
Founded20061989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.